Biohaven Pharmaceutical

Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.

Launch date

Sep 2014

Employees

Market cap

Enterprise valuation

CAD4.4b (Public information from Sep 2024)

New Haven Connecticut (HQ)

http://biohavenpharma.com

https://twitter.com/biohaven https://www.facebook.com/biohaven https://www.linkedin.com/company/biohaven/

Authorizing premium user...